Microvue bap eia kit

Manufactured by Quidel

Sourced in United States

The MicroVue™ BAP EIA kit is a laboratory equipment product designed for the quantitative determination of bone-specific alkaline phosphatase (BAP) in human serum and plasma. The kit provides the necessary components to perform this specific laboratory test.

Automatically generated - may contain errors

Lab products found in correlation

Cellsearch system, by Johnson & Johnson (1 mentions) Cellsearch, by Johnson & Johnson (1 mentions) Microvue osteocalcin eia kit, by Quidel (1 mentions) Microvue pyd eia, by Quidel (1 mentions) Ultra sensitive estradiol ria kit, by Beckman Coulter (1 mentions)

Spelling variants of this product

MicroVue BAP (3 citations) EIA kit (2 citations)

5 protocols using microvue bap eia kit

Circulating Tumor Cells in mCRPC

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

In eligible patients, CTCs were determined no more than 1 week prior to start of the planned treatment (CTC_1). For all patients, a second CTC determination was planned after 2–3 months (CTC_2). For each CTC determination, blood was collected into CellSave Preservation Tubes (Janssen Diagnostics LLC), and 7.5 mL blood was analyzed per sample. Isolation and enumeration of CTCs were carried out using the Food and Drug Association (FDA)-approved CellSearch system (Janssen Diagnostics LLC), with cell interpretation following the standard CellSearch CTC definition.17 (link) Following previous studies in mCRPC patients6 (link),7 (link) a finding of <5 CTCs/7.5 mL blood was defined as “favorable”.
PSA, total ALP, bone-specific ALP (bone-ALP), and LDH were determined at the same days that the CTC determinations took place. LDH and total ALP were measured on a Cobas^® L501 analyzer, while PSA was measured on Cobas L601 analyzer (F Hoffman-La Roche Ltd, Basel, Switzerland). Bone-ALP levels were determined with a MicroVue™ BAP EIA kit (Quidel Corporation, San Diego, CA, USA).

Fosså S.D., Hess S.L., Paus E, & Borgen E. (2014). Circulating tumor cells in patients with metastatic castration resistant prostate cancer: exploratory findings at a tertiary referral hospital. Research and Reports in Urology, 6, 121-126.

+ Open protocol

+ Expand

Bone Turnover Marker Analysis Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

Blood samples were collected in the morning after an overnight fast. Intact parathyroid hormone (PTH), alkaline phosphatase, phosphate, and ionized calcium were analyzed by standardized methods throughout the study period. Blood samples for analysis of bone turnover markers were stored at −80 °C and analyzed in a single batch upon study completion. 25-OH-Vitamin D₂ + D₃ was measured using tandem mass spectrometry. Bone specific alkaline phosphatase (BSAP) was measured using enzyme immunoassay (MicroVue BAP EIA Kit, Quidel®, San Diego, CA, US) with a CV of 6%; C-terminal telopeptide of type I collagen (CTX) was measured by sandwich immunometric assay with a CV of 6%; N-terminal telopeptide of type I collagen (NTX) was measured by competitive immunometric assay with a CV of 10%. P1NP trimer was measured by radioimmunoassay (IDS-iSYS, Fountain Hills, AZ, US), with a CV of 10%, and Tartrate resistant alkaline phosphatase type 5b (TRAP5b) was measured using ELISA (Quidel®, Tecomedical Group, Switzerland), and intra- and inter-assay CVs were both 3%.

Jørgensen H.S., Winther S., Bøttcher M., Hauge E.M., Rejnmark L., Svensson M, & Ivarsen P. (2017). Bone turnover markers are associated with bone density, but not with fracture in end stage kidney disease: a cross-sectional study. BMC Nephrology, 18, 284.

+ Open protocol

+ Expand

Bone Turnover Markers in Exercise

Check if the same lab product or an alternative is used in the 5 most similar protocols

Fasting blood samples were collected in the morning after a 12 h break from the last training session and meal. Blood samples were centrifuged and stored at −80 °C until analysis. The following markers of bone formation were measured before and after the intervention period: osteocalcin (OC, MicroVue™ Osteocalcin EIA kit, Quidel Corporation, San Diego, CA, USA), bone alkaline phosphatase (BAP, MicroVue™ BAP EIA kit, Quidel Corporation, San Diego, CA, USA) and bone resorption: tartrate-resistant acid phosphatase serum band 5 (TRAP 5b, MicroVue™ TRAP 5b EIA kit, Quidel Corporation, San Diego, CA, USA) and α-collagen type 1 cross-linked C-terminal telopeptide (CTX-1, Crosslaps^® CTX-1 ELISA kit, Immunodiagnostic Systems Holdings PLC, Boldon, Great Britain, UK). The serum levels of bone turnover markers were quantified by an enzyme-linked immunosorbent assay. All measurements were performed at the Department of Pediatric Gastroenterology and Metabolic Diseases, Poznan University of Medical Sciences, Poznań, Poland.

Jamka M., Piotrowska-Brudnicka S.E., Karolkiewicz J., Skrypnik D., Bogdański P., Cielecka-Piontek J., Sultanova G., Walkowiak J, & Mądry E. (2022). The Effect of Endurance and Endurance-Strength Training on Bone Health and Body Composition in Centrally Obese Women—A Randomised Pilot Trial. Healthcare, 10(5), 821.

+ Open protocol

+ Expand

Longitudinal Assessment of Bone Biomarkers

Check if the same lab product or an alternative is used in the 5 most similar protocols

Blood and urine samples were taken at baseline and after 3 and 6 months. All samples were collected in the early morning and fasting condition. Blood samples were centrifuged at 10000 × g for 10 min and kept in the fridge at −70°C until analysis. Serum levels of bone biomarkers including OC, BALP, homocysteine, vitamin B12 and urinary concentrations of PYD and β cross laps were measured. Serum OC and β cross laps were quantified by N-MID®Osteocalcin ELISA and Urine BETA CrossLaps® ELISA Immuno Diagnostic Systems (IDS) (Germany), respectively. Urinary PYD and serum level of BALP were measured by MICROVUE PYD EIA® and MICROVUE BAP EIA® Kits from QUIDEL Corporation (Germany), respectively. Serum level of homocysteine was quantified with enzymatic assay by Axis Shield® and serum level of vitamin B12 was measured by the method of chemiluminescence By Diasorin Liaison®. Intra- and inter-assay coefficients of variation (CV) were 2.2% and 5.1% for osteocalcin, 3.9% and 6.9% for β cross laps, 11.2% and 9.9% for PYD, 7.6% and 5.8% for BALP, and 4.4% and 2.2% for homocysteine.

Salari P., Abdollahi M., Heshmat R., Meybodi H.A, & Razi F. (2014). Effect of folic acid on bone metabolism: a randomized double blind clinical trial in postmenopausal osteoporotic women. DARU Journal of Pharmaceutical Sciences, 22(1), 62.

+ Open protocol

+ Expand

Comprehensive Bone Marker Evaluation

Check if the same lab product or an alternative is used in the 5 most similar protocols

Blood was collected by femoral venipuncture after overnight fasting for clinical chemistry (serum calcium, phosphorus, and creatinine; 0.7 mL of blood collected into serum separator tubes) and for bone turnover markers estradiol, PTH(1–84), and 1,25(OH)₂D (6 mL of blood collected into serum separator tubes). Morning urine was collected by catheterization after anesthesia with i.m. glycopyrrolate (0.01 mg/kg), ketamine (5 or 10 mg/kg), xylazine (0.6 mg/kg), or dexmedetomidine (0.01 mg/kg). Serum procollagen 1 N-terminal peptide (P1NP) was measured by UniQ P1NP RIA kits from Orion Diagnostica (Cat. no. 67034), serum bone-specific alkaline phosphatase (BSAP) by MicroVue™ BAP EIA kits from Quidel Corp. (Cat. no. 8012), and serum C-telopeptides (CTX) by Serum CrossLaps ELISA kits (IDS Inc., Cat. no. AC-02F1). Urine N-telopeptides (NTX) was measured by Osteomark NTx Urine ELISA kits (Wampole Laboratories, Cat. no. WL-9006) and adjusted for urine creatinine. Additional serum analyses included estradiol (Ultra-Sensitive Estradiol RIA kit, Beckman Coulter, no. DSL4800), 1,25(OH)₂D (RIA kit, IDS Ltd., no. AA54F2), and PTH(1–84) (human PTH ELISA kit, Immutopics, Inc., no. 60-3100).

Doyle N., Varela A., Haile S., Guldberg R., Kostenuik P.J., Ominsky M.S., Smith S.Y, & Hattersley G. (2017). Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption. Osteoporosis International, 29(3), 685-697.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!